Royce & Associates LP reduced its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 5.8% in the 3rd quarter, HoldingsChannel reports. The firm owned 848,233 shares of the medical device company’s stock after selling 52,357 shares during the quarter. Royce & Associates LP’s holdings in Tandem Diabetes Care were worth $13,835,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Integrated Wealth Concepts LLC purchased a new stake in Tandem Diabetes Care in the 2nd quarter valued at approximately $33,000. Sterling Capital Management LLC increased its position in Tandem Diabetes Care by 849.0% during the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock worth $38,000 after buying an additional 2,080 shares in the last quarter. Fulcrum Asset Management LLP increased its position in Tandem Diabetes Care by 1,463.6% during the third quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock worth $73,000 after buying an additional 4,098 shares in the last quarter. Prosperitas Financial LLC purchased a new position in Tandem Diabetes Care during the second quarter worth $151,000. Finally, Provenance Wealth Advisors LLC acquired a new position in shares of Tandem Diabetes Care in the third quarter worth $158,000.
Tandem Diabetes Care Price Performance
TNDM stock opened at $18.48 on Tuesday. The company has a quick ratio of 2.65, a current ratio of 3.20 and a debt-to-equity ratio of 4.47. Tandem Diabetes Care, Inc. has a one year low of $12.26 and a one year high of $29.65. The company has a 50 day moving average price of $17.37 and a two-hundred day moving average price of $18.83.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.15. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The company had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. During the same period in the previous year, the firm posted ($0.31) EPS. Tandem Diabetes Care’s revenue was up 13.8% on a year-over-year basis. As a group, sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -0.61 EPS for the current fiscal year.
Insider Activity at Tandem Diabetes Care
In other news, Director Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the sale, the director owned 24,434 shares of the company’s stock, valued at $467,911.10. The trade was a 6.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several analysts have recently issued reports on TNDM shares. Citigroup reduced their price objective on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 30th. Wells Fargo & Company dropped their price objective on Tandem Diabetes Care from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, November 6th. UBS Group initiated coverage on shares of Tandem Diabetes Care in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 target price for the company. Truist Financial cut their target price on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, September 24th. Finally, Oppenheimer restated an “outperform” rating on shares of Tandem Diabetes Care in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care has a consensus rating of “Hold” and a consensus price target of $27.18.
Read Our Latest Research Report on Tandem Diabetes Care
Tandem Diabetes Care Company Profile
Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.
Recommended Stories
- Five stocks we like better than Tandem Diabetes Care
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
